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Context:Womenwith type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary
syndrome (PCOS) than the general population.
Objective:Theaimof this studywas to clarify, inDM1womenwithPCOS (PCOS-DM1), the influence
of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences
with age-matched and body mass index (BMI)-matched women with PCOS without diabetes.
Design, Setting, and Patients:Weevaluated 103DM1womenwith andwithout PCOS treatedwith
intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes
were compared in a cross-sectional study.
Outcome Measurements: Clinical, anthropometric, and metabolic parameters were evaluated.
Hormonal evaluation and ovary ultrasound were performed during the follicular phase of the
menstrual cycle.
Results:Applying the diagnostic criteria of the Androgen Excess Society, 38 (36.89%)womenwith
DM1 showed PCOS. The 38 PCOS-DM1 women showed no differences in treatment and glycemic
control compared with DM1 women without PCOS. The only difference was a higher visceral
adiposity index in PCOS-DM1 (1.21  0.70 vs 0.90  0.32; P  .002). PCOS-DM1 showed no phe-
notypic differences with age-matched and BMI-matched PCOS without diabetes. The hormonal
pattern was similar except that higher levels of 4androstenedione were found in PCOS-DM1
(12.89  3.49 vs 2.79  1.75 nmol/L; P  .010).
Conclusions: Thewomenwith PCOS-DM1donot exhibit particular phenotypic characteristics com-
pared with nondiabetic women with PCOS. However, this pathological disorder must not be un-
derestimated because it could be an additional cardiovascular risk factor in women with DM1.
(J Clin Endocrinol Metab 99: 203–211, 2014)
Polycystic ovary syndrome (PCOS) is the commonestendocrine disorder among women of reproductive
age, with a reported prevalence in the general population
of 5% to 10% (1, 2); recently, however, the variability in
the prevalence data (3–5) was found to be related mainly
to the diagnostic criteria used and to the body mass index
(BMI)of the studypopulation, in somecases even reaching
about 20%using theRotterdam criteria (6).Many studies
have demonstrated a significantly high prevalence of clin-
ical hyperandrogenism, menstrual cycle abnormalities, or
overt PCOS in women with diabetes mellitus type 1
(DM1), but the data are discordant due to the different
diagnostic criteria adopted and the difference in the eth-
nicity of the population studied (7–14). In 2000 Escobar-
Morreale et al (7) reported a prevalence of PCOS in 85
Spanishpatientswith aDM1of about 18.8%according to
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the National Institutes of Health criteria (15); this prev-
alence would be higher using the Rotterdam criteria or
those of the Androgen Excess Society (AES) (16). Indeed,
subsequentlyCodner et al (12) studied42Chileanpatients
with DM1 and reported a PCOS prevalence of 40.5%
according to theRotterdamcriteria and31%according to
the AES criteria.
Nevertheless, there are studies that have reported prev-
alence similar to that given in thegeneralpopulation (prev-
alence of 7.4% in 54 Caucasian patients with DM1, ac-
cording to theRotterdamcriteria) (17). In all patientswith
DM1 and PCOS a high frequency of laboratory hyperan-
drogenism was shown.
Although the pathophysiological bases of PCOS in
DM1 are not clear, it has been suggested that exogenous
insulin therapy administered in a nonphysiological fash-
ion could stimulate synthesis of ovarian androgens (18). In
DM1women, through glucotoxicity, chronic hyperglyce-
mia can induce a reduction of peripheral insulin sensitiv-
ity, which sometimes leads to metabolic syndrome and
ovarian hyperandrogenism (19–21).
Exogenous hyperinsulinism at the onset of ovarian
function during puberty could reprogram the ovarian
function toward increased androgen secretion, leading to
hyperandrogenism and PCOS later in life (19).
In this regard Codner et al (12) reported that 75% of
DM1 women on intensive insulin therapy had either
PCOS or asymptomatic polycystic ovarian morphology
on ultrasound scans, as compared with only 33% of pa-
tients on a more conservative conventional therapy using
two daily insulin injections. However, this study and oth-
ers have never shown a real major daily insulin require-
ment (units per kilogram daily) in DM1 women with
PCOS.
The aims of our study were the following:
To clarify, inDM1women, the influence of insulin ther-
apy and glycemic control on the prevalence and pheno-
type of PCOS
To evaluate the phenotypic differences with age-
matched andBMI-matchedwomenwith PCOSwithout
diabetes.
Materials and Methods
Subjects
This studywas approved by the InstitutionalReviewBoard at
the Faculty ofMedicine of the University of Palermo. At the time
of observation all patients regularly signed an informed consent
for the scientific use of their data.
Women with DM1
One hundred twenty-eight consecutive Caucasian postmen-
archeal women with DM1 of reproductive age, followed up in
our dedicated Outpatients Clinic (from January 1, 2011 to De-
cember 31, 2012), were cross-sectionally studied. Inclusion cri-
teria were a 2-year or longer history of DM1 (glutamic acid
decarboxylase antibody positivity at onset of disease and low
C-peptide levels [0.05 ng/mL] during mixed-meal tolerance
test or glucagon stimulation test) at study entry, treated with
insulin from the time of diagnosis. All patients received basal/
bolus insulin therapy (at least fourdaily injections) or continuous
subcutaneous insulin infusion (CSII).
Fifteen patients were excluded because they refused to enter
the study, as well as three pregnant patients, five patients with
autoimmune polyglandular syndrome, and two patients with
hyperprolactinemia. Consequently, 103 women with DM1
(mean: 26.83 y; SD: 6.84; range: 14–42) were studied.
A detailed clinical history was obtained, including age at the
timeof the study, age at diagnosis ofDM1, age ofmenarche, type
of insulin treatment used, daily insulin requirement (units per
kilogram per day), and indexes of metabolic control.
By applying the diagnostic criteria of the AES (16), 38/103
(36.89%) women with DM1 showed a PCOS.
Age- and BMI-matched PCOS women without DM1
A control group of 38 nondiabetic women (matched for age
and BMI) with PCOS (according to the AES criteria) was retro-
spectively selected from our clinical database at the Outpatients
Clinic dedicated to PCOS.The patientswerematched as follows:
for age (16patients basedon exact age, 10 [1y], 2 [2y], 6 [3
y], 4 [4 y] and 1 [5 y], and for BMI 28 patients based on [1
kg/m2], 5 [2 kg/m2], 2 [3 kg/m2], and 3 [4 kg/m2]).
Also, from the two groups the following were excluded: all
women treated with clomiphene citrate, oral contraceptives, an-
tiandrogens, drugs to control their appetite, or insulin-sensitiz-
ing drugs (metformin and pioglitazone) during the 6 months
before the first examination; women with 17OH-progesterone
(17OH-Pg) levels 6.05 nmol/L who, after 250 mg Synacthen
(synthetic analog of adrenocorticotrophic hormone) showed
17OH-Pg30.26 nmol/L at 60 minutes; women with dehydro-
epiandrosterone sulfate (DHEA-S)16.32 mmol/L, who, when
screened with a computerized axial tomography scan, presented
adrenal hyperplasia or adenoma or virilizing androgen-secreting
neoplasias;womenwhose clinical andhormone evaluation (phe-
notype, increased 24-h free urinary cortisol, high cortisol levels
after 1 mg of overnight dexamethasone) suggested Cushing’s
syndrome.
Among all patientswithDM1, eightwere taking angiotensin-
converting-enzyme inhibitors due tomicroalbuminuria and four
were taking angiotensin-converting-enzyme (ACE) inhibitors
due to high blood pressure. Among patients with PCOSwithout
DM1 only three were taking antihypertensive drugs; 10 patients
(sixwithDM1and four control PCOSwithoutDM1)were using
statins due to hypercholesterolemia.
The following relevant data were obtained from our data-
bases: possible family history of diabetes, infertility, and hirsut-
ism; age of menarche, history of prepubertal hypertrichosis, pre-
mature pubarche, and eating disorders; weight, BMI, waist
circumference, blood pressure, and Ferriman–Gallwey (FG)
score. The degree of hirsutism was evaluated using the FG map
scoring system, which divides the body up into 11 domains.
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Hirsutism was defined as FG score 8 (22). Both groups of
women, according tooutpatient practice routine,were trained to
compile a calendar of menstrual cycles. The mean duration of
menstrual cycles (days) of the last 6 months was obtained
for each woman. All patients were tested for FSH, LH, 17-b-
estradiol (E2), 17OH-Pg, basal prolactin, total testosterone,
DHEA-S, 4androstenedione, and SHBG, during the follicular
phase (on the seventh day of the spontaneous menstrual cycle or
7 days after withdrawal of bleeding, administering a single
100-mg im dose of medroxyprogesterone acetate in cases of sec-
ondary amenorrhea [four women with DM1 and PCOS and
three women with PCOS without DM1]). On the same day, we
also tested for total cholesterol, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein cholesterol, triglycerides,
and glycosylated hemoglobin (HbA1c). Serumprogesterone level
was determined between days 20 and 24 of the menstrual cycle
and chronic oligoanovulationwas established if two consecutive
cycles were anovulatory (Pg level 3 ng/mL [International Sys-
tem: 9.54 nmol/L]) (23). Biochemical hyperandrogenism
was diagnosed when androgen levels were as follows: total tes-
tosterone 2.84 nmol/L, DHEA-S 12.14 mmol/L, 4andro-
stenedione 10.72 nmol/L (calculated on the basis of the 95th
percentile upper limits of basal serum androgen concentrations
in 144 healthy normal Sicilian eumenorrheal women without
hirsutism and with no family history of PCOS [used as a control
group in a previous study]) (24). Transvaginal ovarian ultra-
sound scanning was performed between days 5 and 10 after the
beginningof the lastperiodusinga7.5-MHzvaginalprobe trans-
ducer (General Electric LOGIQ 400MD). Both ovaries were
measured in the sagittal, transverse, and coronal planes. Ovaries
were classified as polycystic if 12 or more follicles measuring 2
to 8mm indiameterwere present in each ovary, and/or therewas
an increase in ovarian volume (10 mL) (6, 25, 26).
Assays
All hormones were measured in our laboratory using com-
mercial kits. These included ELISA (DRG Diagnostics; DRG
Instruments GmbH) for FSH (mUI/mL), LH (mUI/mL), 17--E2
(pg/mL), 17OH-Pg (ng/mL), Pg (ng/mL), PRL (ng/mL), total tes-
tosterone (ng/mL),4androstenedione (ng/mL; Arnika), and in-
sulin (mUI/L; the intra- and interassay coefficient of variance
were 4% and 3.6%, respectively). Chemiluminescence as-
says were used for DHEA-S (g/dL; Immulite, Diagnostic Prod-
ucts) and serumSHBG (nmol/L; Immulite;Diagnostic Products).
Blood glucose levels (mg/dL) were measured using an electro-
chemical system (Glucocard; Menarini Diagnostics). Total cho-
lesterol,HDL, and triglyceridesweremeasured inour laboratory
using standard assays. HbA1c was determined by HPLC with
ion-exchange resin (HA8121; Hi-AutoA1c). HDL cholesterol
levels were calculated with Friedewald’s formula. The conver-
sion factors for the International System were the following:
glucose (mg/dL vs mmol/L: 0.0555), insulin (mUI/L vs pmol/L:
6.945), total cholesterol (mg/dL vs mmol/L: 0.0259), total tes-
tosterone (ng/mL vs nmol/L: 3.467), free testosterone (pg/mL vs
pmol/L: 3.47), DHEA-S (g/dL vs mmol/L: 0.0272), 4an-
drostenedione (ng/mL vs nmol/L: 3.492), 17--E2 (pg/mL vs
pmol/L: 3.671), 17OH-Pg (ng/mL vs nmol/L: 3.026), Pg (ng/mL
vs nmol/L: 3.180), PRL (ng/mL vs g/L: 1), FSH (mUI/mL vs
IU/L: 1), and LH (mUI/mL vs IU/L: 1).
Free androgen index (FAI) was calculated as the ratio of total
testosterone levels in nmol/L to SHBG levels in nmol/Lt  100
(%) (27).
Visceral adiposity index (VAI) was calculated as described
(28, 29) using the following sex-specific equation, where TG is
triglyceride levels expressed in mmol/L and HDL is HDL cho-
lesterol levels expressed in mmol/L:
Females: VAI WC36.58  (1.89  BMI)   TG0.81   1.52HDL
Statistical methods
The SPSS version 17 andMedCalc version 11.3were used for
data analysis. Baseline characteristics were presented as mean
SD for continuous variables; rates and proportions were calcu-
lated for categorical data. Normality of distribution for quanti-
tative datawas assessedby the Shapiro-Wilk test. Thedifferences
between the two groups were detected by the unpaired Student’s
t test for continuous variables (after testing for equality of
variance: Levene test) and by the 2 test and Fisher’s exact test
(when appropriate) for categorical variables. To evaluate the
independent metabolic variables influencing several hor-
monal parameters, in all DM1 women linear regression mod-
els were performed.
TheANOVAwas used for comparison of the same hormonal
variables between groups (DM1 without PCOS, DM1 with
PCOS, and PCOS without DM1) after testing for equality of
variance. The Fisher least significant difference post-hoc correc-
tion was applied if the variables had equal variances and the
Dunnett post-hoc correction was applied if the variables did not
have equal variances.
For comparison between women with DM1 (with and with-
out PCOS), the group sizes gave 78.44%power to detect a mod-
erate effect size (Cohen’s d  0.5) using t test, with  at 0.05.
For comparison between women with PCOS (with and with-
out DM1), the group sizes gave 69.65% power to detect a mod-
erate effect size (Cohen’s d  0.5) using t test, with  at 0.05.
Post-hoc power analysis was performed using G*Power Version
3.1.6 software (Franz Faul, University of Kiel, Germany).
A P value of .05 was considered statistically significant.
Results
Women with DM1 show a PCOS prevalence of 36.89%
(38/103). Regarding age at onset of diabetes, no differ-
ences were found between diabetic womenwith andwith-
out PCOS and the prevalence of patients with prepubertal
onset of diabetes was similar in the two groups (6/38
[15.8%] vs 14/65 [21.5%]; P  .477).
DM1 women with PCOS showed a higher prevalence
of family history for hirsutism (10.0% vs 0%; P .017),
premature pubarche (13.2% vs 1.5%; P  .025), poly-
cystic ovary morphology (PCOM) (73.7% vs 7.7%; P 
.001), oligo/amenorrhea (81.6% vs 7.7%; P .001), hir-
sutism (97.4% vs 4.6%; P .001), acne/seborrhea (50%
vs 12.3%; P .001), and hyperandrogenemia (71.1% vs
3.1%; P  .001). DM1 women without PCOS showed a
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higher mean number of successful pregnancies than DM1
women with PCOS (0.55  0.84 vs 0.18  0.45; P 
.015). In addition, diabetic women with PCOS had a sig-
nificantly higher LH/FSH ratio (1.35  0.55 vs 0.69 
0.28; P .001), higher levels of 17OH-Pg (1.35 0.55 vs
0.69 0.28 nmol/L; P .001), total testosterone (2.95
0.94 vs 1.49  0.62 nmol/L; P  .001), 4androstene-
dione (12.893.49vs7.261.92nmol/L;P .001), and
significantly lower levels of 17--E2 (246.03  68.15 vs
363.03  101.43 pmol/L; P  .001) and Pg in the luteal
phases (3.88 6.36 vs 25.57 17.20 nmol/L; P .001);
no significant differencewas found for all other hormonal
parameters investigated (Table 1). Regarding metabolic
parameters, only VAI (1.21  0.70 vs 0.90  0.32; P 
.002) and triglycerides (1.00.52vs0.750.44mmol/L;
P .013) were significantly higher in patients with PCOS
(Figure 1); no differences were found for glycemic com-
pensation (HbA1c), daily insulin requirement, and type of
basal insulin used (Table 1). In all DM1 women, the hor-
monal parameters that showed significant differences be-
tween the two groups (LH, 17--E2, 17OH-Pg, total tes-
tosterone, 4androstenedione, and Pg) were analyzed in
Table 1. Clinical, Anthropometric, and Biochemical Characteristics of 103 Women With DM1 With and Without
PCOSa
Subjects (%) Subjects (%)
DM1 Without
PCOS (N  65)
Mean  SD
DM1 With PCOS
(N  38)
Mean  SD P
Age, y 27.57  7.07 25.55  5.01 .126
BMI, kg/m2 21.60  2.98 22.79  3.80 .102
Waist circumference, cm 77.89  7.90 80.57  10.63 .181
Birth weight, kg 3.31  0.60 3.08  0.59 .102
Age of menarche, y 12.65  1.16 12.44  1.40 .457
FG score 2.47  2.68 10.13  5.30 .001
Age at onset of diabetes, y 19.27  8.61 16.68  5.36 .097
Mean duration of menstrual cycles, d 28.61  3.81 46.10  15.06 .001
Successful pregnancies 0.55  0.84 0.18  0.45 .015
Miscarriages 0.18  0.46 0.27  0.60 .460
Premenarchal onset of diabetes 14 (21.5) 6 (15.8) .477
Prepubertal hypertrichosis 0 1 (2.6) .369
Premature pubarche 1 (1.5) 5 (13.2) .025
Eating disorders 1 (1.5) 1 (2.6) .317
Current or former smokers 12 (19.1) 10 (27.7) .490
Family history
Family history for diabetes 54 (83.1) 32 (84.2) .881
Family history for infertility 0 1 (2.6) .369
Family history for hirsutism 0 4 (10.5) .017
Hormonal profiles
FSH, IU/L 7.14  2.14 6.55  2.28 .388
LH, IU/L 4.61  1.42 8.05  2.76 .001
LH/FSH 0.69  0.28 1.35  0.55 .001
17--E2, pmol/L 363.03  101.43 246.03  68.15 .001
17OH-Pg, nmol/L 2.39  1.00 3.30  1.09 .017
Pg, nmol/L 25.57  17.20 3.88  6.36 .001
Total testosterone, nmol/L 1.49  0.62 2.95  0.94 .001
SHBG, nmol/L 90.72  37.80 101.47  40.53 .387
FAI (100  [total testosterone/SHBG]), % 0.73  0.62 0.95  0.69 .383
DHEA-S, mol/L 6.16  1.86 7.96  4.97 .129
4androstenedione, nmol/L 7.26  1.92 12.89  3.49 .001
Glycemic compensation
HbA1c, % 8.42  1.40 8.63  1.67 .508
Insulin therapy
Rapid-acting analogs IR, U/kg 0.43  0.15 0.41  0.12 .528
Basal analogs IR, U/kg 0.28  0.11 0.29  0.09 .680
Total IR, U/kg 0.71  0.21 0.71  0.16 .856
Basal insulin therapy
Glargine 36 (55.4) 18 (47.4) .635
Detemir 22 (33.8) 13 (34.2)
Neutral protamine lyspro 4 (6.2) 4 (10.5)
CSII 3 (4.6) 3 (7.9)
Abbreviation: IR, insulin requirement.
a According to Consensus Statement by the Androgen Excess and PCOS (AE-PCOS) Society (2010), univariate analysis: qualitative variables were analyzed
through the 2 test or Fisher exact test; quantitative variables were analyzed through Student’s t test after testing for equality of variance (Levene test).
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several multiple linear regressionmodels, in which the de-
pendent variables were represented by the metabolic pa-
rameters HbA1c, VAI, age at onset of diabetes, and insulin
requirement. In this multivariate analysis, VAI was the
onlymetabolic variable independently associatedwithLH
( 0.46; P .003) and age of onset of diabetes was the
only variable independently associated with Pg in the lu-
teal phases (  0.34; P  .028) (Supplemental Table 1,
published on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org).
PCOS women with DM1 (PCOS-DM1) vs PCOS
women without DM1 (PCOS-NO-DM1)
No significant differences in PCOS phenotype (using
the AES diagnostic criteria) were found between PCOS-
DM1 and PCOS-NO-DM1 (Tables 2 and 3). Instead, a
significantly higher prevalence of prepubertal hypertri-
chosis (36.8% vs 2.6%; P  .001), family history for in-
fertility (37.5 vs 2.6; P  .013), and family history for
hirsutism (45.2% vs 10.5%; P  .002) was found in
PCOS-NO-DM1. PCOS-DM1 women showed a higher
Figure 1. VAI and lipid profile in women with DM1 (with and without PCOS) and in women with PCOS without diabetes.
Table 2. Prevalence of All Possible Phenotypes Based on the Presence or Absence of Oligo-Anovulation,
Hyperandrogenemia, Hirsutism, and PCOM, Using AES Criteria, in PCOS Women Without DM1 and in PCOS Women
With DM1
Potential Phenotypes
A B C D E F G H I
Hyperandrogenemia X X X X X X
Hirsutism X X X X X X
Oligo-anovulation X X X X X X
PCOM X X X X X X
PCOS women with
DM1a
13 (34.2) 9 (23.7) 1 (2.6) 9 (23.7) 1 (2.6) 4 (10.5) 1 (2.6)
PCOS women without
DM1a
9 (23.7) 5 (13.2) 4 (10.5) 2 (5.3) 4 (10.5) 5 (13.2) 1 (2.6) 4 (10.5) 4 (10.5)
Pb .448 .374 .357 .493 .222 .199 .357 .357 .115
a Values are expressed as number (%).
b Univariate analysis: 2 test or Fisher exact test.
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waist circumference than PCOS-NO-DM1 women
(80.57  10.63 vs 72.86  8.03 cm; P  .001).
Regarding the hormonal data, PCOS-DM1 only showed
significantly higher levels of 4androstenedione than
PCOS-NO-DM1 women (12.89  3.49 vs 9.74  6.11
nmol/L; P  .010). No differences were found for the
metabolic profile, except for significantly lower levels of
HDL cholesterol in PCOS-NO-DM1 (1.41  0.27 vs
1.64  0.38 mmol/L; P  .004) (Figure 1).
To confirm what was found in the two separate statistical
approaches, a univariate ANOVAwith post-hoc test was per-
formedbetweenthethreegroups(DM1withoutPCOS,PCOS-
DM1,andPCOS-NO-DM1)forthehormonalparametersthat
were significantly higher in PCOS-DM1 comparedwithDM1
without PCOS (Supplemental Table 2).
Discussion
Our study confirms the well-known higher prevalence of
PCOS inwomenwithDM1 than in the general population
(7–14). However, in some previous studies, a precise di-
agnostic criterion for PCOS has not always been applied;
in some cases only an increased prevalence of menstrual
disturbances, hirsutism, and polycystic ovarian morphol-
ogy has been reported in women with DM1.
In our opinion, the application of a criterion such as
that proposed by the National Institutes of Health or by
the AES (which requires the necessary presence of a con-
dition of hyperandrogenism) is a very important point for
the diagnosis of PCOS in women with DM1. In this con-
nection, applying the Rotterdam criteria, we could mis-
takenly make a diagnosis of PCOS in women with DM1
that due to a long period of glycemic decompensation
may develop a transient ovulatory phenotype without
hyperandrogenism.
Unfortunately, our study, like most studies on the sub-
ject, was not able to identify the precise cause of this in-
creasedprevalence comparedwith the general population.
Our main finding was the observation of a similar in-
sulin requirement in DM1 women with and without
Table 3. Clinical, Anthropometric, and Biochemical Differences Between 38 PCOS Women With DM1 and 38
Age-Matched and BMI-Matched PCOS Women Without DM1
Subjects (%) Subjects (%)
PCOS Women
With DM1
(N  38)
Mean  SD
PCOS Women
Without DM1
(N  38)
Mean  SD P
Age, y 25.55  5.01 24  2.68 .096
BMI, kg/m2 22.79  3.80 23.15  1.75 .598
Waist circumference, cm 80.57  10.63 72.86  8.03 .001
Birth weight, kg 3.08  0.59 2.83  0.73 .094
Age of menarche, y 12.44  1.40 12.00  1.09 .126
FG score 10.13  5.30 11.76  6.29 .226
Mean duration of menstrual cycles, d 46.10  15.06 47.39  21.04 .760
Successful pregnancies 0.18  0.45 0.18  0.51 1
Miscarriages 0.27  0.60 0.10  0.38 .164
Prepubertal hypertrichosis 1 (2.6) 14 (36.8) .001
Premature pubarche 5 (13.2) 5 (13.2) 1
Eating disorders 1 (2.6) 1
Current or former smokers 10 (27.7) 7 (18.4) .582
Family history
Family history for diabetes 32 (84.2) 26 (68.42) .177
Family history for infertility 1 (2.6) 3 (37.5) .013
Family history for hirsutism 4 (10.5) 14 (45.2) .002
Hormonal profiles
FSH, IU/L 6.55  2.28 6.50  2.41 .941
LH, IU/L 8.05  2.76 8.50  4.19 .606
LH/FSH 1.35  0.55 1.40  0.75 .769
17--E2, pmol/L 199.48  74.19 173.01  81.17 .142
17OH-Pg, nmol/L 3.30  1.09 3.54  1.76 .523
Pg, nmol/L 3.88  6.36 8.14  9.95 .054
Total testosterone, nmol/L 2.95  0.94 2.57  1.73 .243
SHBG, nmol/L 101.47  40.53 91  51.80 .441
FAI (100  [total testosterone/SHBG]), % 0.95  0.69 1.37  1.58 .203
DHEA-S, mol/L 7.96  4.97 8.51  4.25 .635
4androstenedione, nmol/L 12.89  3.49 9.74  6.11 .010
a According to Consensus Statement by the Androgen Excess and PCOS (AE-PCOS) Society (2010); Univariate analysis: qualitative variables were
analyzed through 2 test or Fisher exact test; quantitative variables were analyzed through Student’s t test after testing for equality of variance
(Levene test).
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PCOS. The link to the insulin requirement was not found
that was observed in other studies, in which it was sug-
gested that exogenous hyperinsulinemia may contribute
to PCOSdevelopment by enhancing androgen production
(12,18–21).This couldbedue to the fact that some studies
have not quantified the total insulin requirement, limiting
the distinction between conventional and intensive insulin
therapy (12). The link between PCOS and DM1 could
involve supraphysiological concentrations of insulin
within the systemic circulation,whichdoes not necessarily
correlate with insulin requirement or with type of insulin
treatment. In women with DM1, subcutaneously admin-
istered insulin leaves out the first hepatic passage and leads
to abnormally high insulinemia, which can interfere with
ovarian function (30). Our study also showed no differ-
ences in the distribution of the different modes of insulin
administration (multiple daily injections, CSII) and in the
various types of insulin analogs used in diabetic women
with PCOS and without PCOS. This finding is confirmed
by a systematic review that reported no significant differ-
ences between multiple daily injection and CSII in the pe-
ripheral effects of hyperinsulinemia (31). Furthermore,
the fact that our DM1women with PCOS did not present
a higher HbA1c cannot exclude the influence of glucose
toxicity in the pathogenesis of PCOS suggested by some
studies (19, 30, 32); in this connection, rather than the
existing glycemic control, it would be interesting to know
the status of glucose toxicity during puberty (20). Fur-
thermore, in the case of onset of diabetes before puberty,
strong exposure to exogenous insulin during pubertal de-
velopmentmayunmaskaPCOS ingeneticallypredisposed
girls. In this regard, in our study, although themean age of
menarche was lower in womenwithDM1 and PCOS, this
datum showed borderline statistical significance, proba-
bly due to the small sample size. These issues should be
further investigated through prospective studies involving
girls with onset of diabetes before menarche.
The only aspects that characterize the presence of
PCOS inourpopulationofwomenwithDM1are agreater
number of cases of family history for hirsutism, lower
levels of 17--E2 in the follicular phase, lower levels of Pg
in the luteal phase, an increase in the LH/FSH ratio, and
hyperandrogenemia.
An unexpected finding is the lack of an increase in FAI
in women with DM1 and PCOS, despite the significantly
higher levels of total testosterone. This is attributable to
the absence of significant differences in the SHBG levels,
which could be explained by a condition of exogenous
hyperinsulinization that may involve all women with
DM1 (with or without PCOS). In fact, there is evidence to
suggest that hyperinsulinism may inhibit the hepatic syn-
thesis of SHBG (33).
It would seem that in genetically predisposed women
with DM1, exogenous insulin therapy and insulin resis-
tance caused by glucose toxicity could increase the activity
of several steroidogenic enzymes (CYP17, p450scc, 3--
HSD) (34), which may lead to the hyperandrogenism ob-
served in women with T1D and PCOS (12).
An interesting datum emerging from our study is the
increased cardiometabolic risk in women with DM1 and
PCOS, indirectly expressed by high VAI and triglyceride
levels. VAI being an index of impaired fat distribution and
function, in addition to indirectly expressing altered pro-
duction, release, and/or function of adipocytokines and
inflammatory factors, involved in the genesis of PCOS
(35), also expresses a condition of cardiometabolic risk
(24, 28, 36). Recently, in a population of young women
with PCOS,VAI proved to be able to replace visceral com-
puted tomographic scanning as a marker for visceral ad-
iposity and to predict insulin resistance (37). These find-
ings have led to the proposal of a precise VAI cutoff to
differentiate metabolically healthy PCOS from metaboli-
cally unhealthy PCOS (38). However, in our study, DM1
womenwith PCOS,while presenting a higherVAI, did not
showan increased insulin requirement. This datumwould
seem to conflict with the alleged lower insulin sensitivity
of DM1 women with PCOS. In fact, insulin requirement,
in type 1 persons with diabetes, is not a good surrogate of
insulin sensitivity, because in addition to reflecting the
degreeof insulin sensitivity, it is also influencedby residual
pancreatic function and by variability in absorption of
insulin in subcutaneous adipose tissue. In the future, a
study using the hyperinsulinemic euglycemic clamp could
clarify this aspect.
Regarding comparison with nondiabetic women with
PCOS, applying the AES criteria, no substantial pheno-
typic differences were observed except for an increased
production of4androstenedione in diabeticwomenwith
PCOS. Moreover, the impact of genetics (family history
for infertility and hirsutism) was more striking in nondi-
abetic women with PCOS. The hormone profiles of DM1
patients with PCOS seem comparable to that of nondia-
betic women with PCOS. In the former, the higher levels
of 4androstenedione, also observed in other studies (12,
39), suggest that inDM1womenwith PCOS the androgen
excess appears to be mostly of ovarian origin (40, 41).
A limit of the study is, however, the small sample of
women with PCOS and DM1; this made it impossible to
perform a valid statistical analysis to compare DM1
women without PCOS with the various phenotypes of
PCOS.
Weconclude that inDM1,PCOSpresents noparticular
phenotypic characteristics compared with PCOS in non-
diabetic women. However, the diagnostic framing re-
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mainsof fundamental importance, because thepresenceof
PCOS, and therefore of a condition of insulin resistance,
could be an additional cardiometabolic risk factor in
women with DM1 (42, 43). Hyperandrogenemia is often
the most reliable finding in these patients, and it may be
prudent todefinediabeticwomenwithPCOSaccording to
the AES criteria.
In addition, given the evidence for PCOS as a complex
genetic disorder with familial clustering, it is important to
ascertain the family history for both PCOS and metabolic
disease. In diabetic women with poor glycemic compen-
sation without pronounced hyperandrogenism, it is pref-
erable to monitor the symptoms and repeat PCOS evalu-
ation after improvement in glycemic profile.
Finally, in the future the scientific community should
use unique diagnostic criteria to better understand the
pathophysiological mechanisms underlying the syndrome
and to define the best therapeutic approach.
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